BackShield Therapeutics plc Overview
Shield Therapeutics plc

Shield Therapeutics plc Return on Equity

Shield Therapeutics plc (SHIEF) has a ROE of 185.96%, above the sector sector average of 11.3%.

Get informed when a big investor buys or sells

+ Follow

ROE

185.96%

Return on Equity

185.96%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Shield Therapeutics plc (SHIEF) FAQ

Shield Therapeutics plc (SHIEF) currently reports a ROE of 185.96%. That is above the sector sector average of 11.3%. Use the charts on this page to explore Shield Therapeutics plc's ROE history and peer comparisons.

Shield Therapeutics plc's ROE of 185.96% is higher than the its sector sector average of 11.3%. That is roughly 1546.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Shield Therapeutics plc's current 185.96% should be judged against industry norms (sector average: 11.3%) and against SHIEF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 185.96%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.3%. From there, open related valuation or income-statement pages for Shield Therapeutics plc, and consider following SHIEF for alerts when major investors trade the stock.

Questions & Answers